A Phase III Randomized, Placebo Controlled, Double Blind

Project: Research project

Project Details

Description

A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line Systemic Treamtent for Hepatocellular Carcinoma (HCC)
StatusFinished
Effective start/end date10/13/0910/31/15

Funding

  • BAYER HEALTHCARE PHARMACEUTICALS